Colin Rueda
Overview
Explore the profile of Colin Rueda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
2
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa B, Nishimura N, et al.
Blood Cancer J
. 2024 May;
14(1):88.
PMID: 38821925
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell...
2.
Hamadeh I, Shekarkhand T, Rueda C, Firestone R, Wang A, Korde N, et al.
Blood Adv
. 2024 Apr;
8(12):3038-3044.
PMID: 38598713
Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study...
3.
Lesokhin A, Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa B, et al.
Res Sq
. 2024 Feb;
PMID: 38405866
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell...